Share on LinkedInShare on LinkedIn

ARTICLE · 10 JULY 2023

It's Time To Review Patent Eligibility For Diagnostic Methods

Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Contributor
Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Finnegan, Henderson, Farabow, Garrett & Dunner LLP is one of the world’s largest firms focusing on...

View firm profile
Explore more from Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Life science companies invest substantial resources in research and innovation to drive medical advancement.

United StatesIntellectual Property

Life science companies invest substantial resources in research and innovation to drive medical advancement. To maintain the momentum of innovation, it is crucial to ensure clarity and certainty in patent eligibility.

The US Supreme Court in Mayo Collaborative Servs v Prometheus Lab'ys (2012), ruled that the diagnostic patents in suit were invalid because they merely described the natural correlation between the drug's metabolite levels in the blood and its effectiveness. Following Mayo, the Supreme Court, in Alice v CLS Bank Int'l (2014), articulated a two-step test for examining patent eligibility under 35 U.S.C. § 101.

Under this test, a patent claim is ineligible if it 1) is directed to a patent-ineligible concept (such as laws of nature, natural phenomena, and abstract ideas), and 2) lacks elements sufficient to transform the claim into a patent-eligible application.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from